TY - JOUR
T1 - Long-Term Outcomes After Edge-to-Edge Repair of Secondary Mitral Regurgitation
T2 - 5-Year Results From the EuroSMR Registry
AU - EuroSMR Investigators
AU - Stocker, Thomas J.
AU - Stolz, Lukas
AU - Karam, Nicole
AU - Kalbacher, Daniel
AU - Koell, Benedikt
AU - Trenkwalder, Teresa
AU - Xhepa, Erion
AU - Adamo, Marianna
AU - Spieker, Maximilian
AU - Horn, Patrick
AU - Butter, Christian
AU - Weckbach, Ludwig T.
AU - Novotny, Julia
AU - Melica, Bruno
AU - Giannini, Christina
AU - von Bardeleben, Ralph Stephan
AU - Pfister, Roman
AU - Praz, Fabien
AU - Lurz, Philipp
AU - Rudolph, Volker
AU - Metra, Marco
AU - Hausleiter, Jörg
AU - Doldi, Philipp
AU - Näbauer, Michael
AU - Massberg, Steffen
AU - Popescu, Aniela
AU - Ruf, Tobias
AU - Iliadis, Christos
AU - Baldus, Stephan
AU - Besler, Christian
AU - Kister, Tobias
AU - Kresoja, Karl
AU - Thiele, Holger
AU - Ludwig, Sebastian
AU - Pauschinger, Christoph
AU - Schofer, Niklas
AU - Neuss, Michael
AU - Joner, Michael
AU - Omran, Hazem
AU - Fortmeier, Vera
AU - Gerçek, Muhammed
AU - Zweck, Elric
AU - Kassar, Mohammad
AU - Windecker, Stephan
AU - Puscas, Tania
AU - Lupi, Laura
AU - Pancaldi, Edoardo
AU - Tomasoni, Daniela
AU - Petronio, Anna
AU - Sampaio, Francisco
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/11/11
Y1 - 2024/11/11
N2 - Background: Mitral valve transcatheter edge-to-edge repair (M-TEER) reduces secondary mitral regurgitation (MR) in heart failure and impacts survival in selected patients as demonstrated in the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial. However, long-term outcome data after M-TEER under real-world conditions are lacking. Objectives: This study sought to assess long-term efficacy and survival after M-TEER in a large real-world registry. Methods: We analyzed patients with significant secondary MR undergoing M-TEER from the EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry. Long-term MR reduction, functional outcomes, survival rate, and predictors for all-cause mortality were assessed. Results: In this study, 1,628 patients undergoing M-TEER (mean age 73.8 years, mean EuroSCORE II [European System for Cardiac Operative Risk Evaluation II] 6.9%, 86.6% NYHA functional class ≥III) with available long-term data were included. Five-year survival was 35.0%. Long-term MR reduction (MR grade ≤2+: baseline 4.1%, discharge 92.2%, 5-year follow-up 85.5%; P < 0.001) and functional improvement (NYHA ≤II: baseline 13.4%, 5-year follow-up 60.1%; P < 0.001) was observed. The degree of residual MR was associated with 5-year survival (residual MR grade ≤1+: 38.6%; 2+: 30.5%; ≥3+: 22.6%; P < 0.001). Independent predictors for 5-year all-cause mortality post–M-TEER included age, renal function, residual MR, NYHA functional class, left ventricular ejection-fraction, and COAPT trial eligibility (P < 0.01 for all). Conclusions: This extensive multicenter registry underscores the long-term efficacy of M-TEER in real-world clinical practice and identifies predictors for long-term survival. These findings contribute valuable insights for optimizing patient selection in routine clinical interventions.
AB - Background: Mitral valve transcatheter edge-to-edge repair (M-TEER) reduces secondary mitral regurgitation (MR) in heart failure and impacts survival in selected patients as demonstrated in the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial. However, long-term outcome data after M-TEER under real-world conditions are lacking. Objectives: This study sought to assess long-term efficacy and survival after M-TEER in a large real-world registry. Methods: We analyzed patients with significant secondary MR undergoing M-TEER from the EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry. Long-term MR reduction, functional outcomes, survival rate, and predictors for all-cause mortality were assessed. Results: In this study, 1,628 patients undergoing M-TEER (mean age 73.8 years, mean EuroSCORE II [European System for Cardiac Operative Risk Evaluation II] 6.9%, 86.6% NYHA functional class ≥III) with available long-term data were included. Five-year survival was 35.0%. Long-term MR reduction (MR grade ≤2+: baseline 4.1%, discharge 92.2%, 5-year follow-up 85.5%; P < 0.001) and functional improvement (NYHA ≤II: baseline 13.4%, 5-year follow-up 60.1%; P < 0.001) was observed. The degree of residual MR was associated with 5-year survival (residual MR grade ≤1+: 38.6%; 2+: 30.5%; ≥3+: 22.6%; P < 0.001). Independent predictors for 5-year all-cause mortality post–M-TEER included age, renal function, residual MR, NYHA functional class, left ventricular ejection-fraction, and COAPT trial eligibility (P < 0.01 for all). Conclusions: This extensive multicenter registry underscores the long-term efficacy of M-TEER in real-world clinical practice and identifies predictors for long-term survival. These findings contribute valuable insights for optimizing patient selection in routine clinical interventions.
KW - heart failure
KW - long-term follow-up
KW - mitral regurgitation
KW - mitral valve transcatheter edge-to-edge repair
UR - http://www.scopus.com/inward/record.url?scp=85207754723&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2024.08.016
DO - 10.1016/j.jcin.2024.08.016
M3 - Article
AN - SCOPUS:85207754723
SN - 1936-8798
VL - 17
SP - 2543
EP - 2554
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 21
ER -